
|Articles|August 19, 2019
ASRS 2019 Street Team: Raj K. Maturi, MD
Author(s)Julianne Mobilian
ICYMI: Abicipar Phase II MAPLE Trial supports improved safety for patients with nAMD following a Modified Manufacturing Process
Advertisement
Raj K. Maturi, MD, discusses phase II data from the abicipar Phase II MAPLE Trial for patients with AMD at the 2019 annual ASRS conference.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery
2
Oku Digital Health launches from Topcon to link eye care, primary care
3
EURETINA 2026: Optogenetic therapy MCO-010 aims to restore vision in advanced macular disease
4
EURETINA 2026: Eyestem interim Phase 2 results for clinical study of Eyecyte-RPE for GA secondary to dry AMD
5



















